Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Nat Genet ; 25(4): 402-5, 2000 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10932182

RESUMO

Neurofibrillary tangles (NFT) composed of the microtubule-associated protein tau are prominent in Alzheimer disease (AD), Pick disease, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Mutations in the gene (Mtapt) encoding tau protein cause frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), thereby proving that tau dysfunction can directly result in neurodegeneration. Expression of human tau containing the most common FTDP-17 mutation (P301L) results in motor and behavioural deficits in transgenic mice, with age- and gene-dose-dependent development of NFT. This phenotype occurred as early as 6.5 months in hemizygous and 4.5 months in homozygous animals. NFT and Pick-body-like neuronal lesions occurred in the amygdala, septal nuclei, pre-optic nuclei, hypothalamus, midbrain, pons, medulla, deep cerebellar nuclei and spinal cord, with tau-immunoreactive pre-tangles in the cortex, hippocampus and basal ganglia. Areas with the most NFT had reactive gliosis. Spinal cord had axonal spheroids, anterior horn cell loss and axonal degeneration in anterior spinal roots. We also saw peripheral neuropathy and skeletal muscle with neurogenic atrophy. Brain and spinal cord contained insoluble tau that co-migrated with insoluble tau from AD and FTDP-17 brains. The phenotype of mice expressing P301L mutant tau mimics features of human tauopathies and provides a model for investigating the pathogenesis of diseases with NFT.


Assuntos
Neurite do Plexo Braquial/genética , Transtornos dos Movimentos/genética , Emaranhados Neurofibrilares/genética , Proteínas tau/genética , Substituição de Aminoácidos , Animais , Tronco Encefálico/metabolismo , Tronco Encefálico/patologia , Tronco Encefálico/ultraestrutura , Contagem de Células , Expressão Gênica , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos DBA , Camundongos Transgênicos , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Músculo Esquelético/ultraestrutura , Mutação , Neurônios/patologia , Neurônios/ultraestrutura , Medula Espinal/metabolismo , Medula Espinal/patologia , Medula Espinal/ultraestrutura
2.
J Cereb Blood Flow Metab ; 34(10): 1637-45, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25052558

RESUMO

In our juvenile traumatic brain injury (jTBI) model, emergence of cognitive dysfunctions was observed up to 6 months after trauma. Here we hypothesize that early brain injury induces changes in the neurovascular unit (NVU) that would be associated with amyloid-beta (Aß) accumulation. We investigated NVU changes for up to 6 months in a rat jTBI model, with a focus on the efflux protein P-glycoprotein (P-gp) and on the basement membrane proteins perlecan and fibronectin, all known to be involved in Aß clearance. Rodent-Aß staining is present and increased after jTBI around cerebral blood microvessels, and the diameter of those is decreased by 25% and 34% at 2 and 6 months, respectively, without significant angiogenesis. P-glycoprotein staining in endothelium is decreased by 22% and parallels an increase of perlecan and fibronectin staining around cerebral blood vessels. Altogether, these results strongly suggest that the emergence of long-term behavioral dysfunctions observed in rodent jTBI may be related to endothelial remodeling at the blood-brain barrier alongside vascular dysfunction and altered Aß trafficking. This study shows that it is important to consider jTBI as a vascular disorder with long-term consequences on cognitive functions.


Assuntos
Peptídeos beta-Amiloides/metabolismo , Lesões Encefálicas/patologia , Encéfalo/irrigação sanguínea , Encéfalo/patologia , Animais , Barreira Hematoencefálica/metabolismo , Barreira Hematoencefálica/patologia , Encéfalo/metabolismo , Lesões Encefálicas/metabolismo , Fibronectinas/análise , Fibronectinas/metabolismo , Proteoglicanas de Heparan Sulfato/análise , Proteoglicanas de Heparan Sulfato/metabolismo , Masculino , Microcirculação , Ratos , Ratos Sprague-Dawley
3.
Brain Res ; 1505: 61-7, 2013 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-23415649

RESUMO

ß-Amyloid (Aß), a small, fibrillogenic peptide, is known to play an important role in the pathogenesis of Alzheimer's disease (AD) in the brain. In addition, Aß accumulates in skeletal muscle cells in individuals with sporadic inclusion body myositis (sIBM), an age-related muscle disease. Because of the socioeconomic burden associated with age-related diseases, particularly AD, there has been considerable emphasis on studying potential therapeutic strategies. The high-fat, low carbohydrate ketogenic diet has been used extensively to treat refractory childhood epilepsy and has been studied as a potential treatment for other neurological diseases, including Parkinson's disease and AD. In this study, we fed young APP/PS1 knock-in mice, which have a whole body knock-in of AD-related genes, a ketogenic diet and determined the effect on Aß levels in the brain and skeletal muscle, as well motor performance and oxidative stress. Aß and its precursor, the ß-C-terminal fragment of amyloid precursor protein (CTFß), were unchanged overall in both the brain and quadriceps after 1 month on the ketogenic diet, and there was no effect on nitrotyrosine, a product of oxidative stress. The ketogenic diet improved performance on the Rota-rod apparatus (p=0.007), however. These data indicate that the ketogenic diet may have some efficacy in the treatment of both neurologic and muscle diseases though the underlying mechanisms do not involve amelioration of Aß pathology.


Assuntos
Doença de Alzheimer/dietoterapia , Doença de Alzheimer/metabolismo , Peptídeos beta-Amiloides/metabolismo , Dieta Cetogênica/métodos , Transtornos dos Movimentos/dietoterapia , Fatores Etários , Doença de Alzheimer/complicações , Doença de Alzheimer/genética , Precursor de Proteína beta-Amiloide/genética , Animais , Encéfalo/metabolismo , Encéfalo/patologia , Modelos Animais de Doenças , Humanos , Camundongos , Camundongos Transgênicos , Transtornos dos Movimentos/etiologia , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Presenilina-1/genética , Tempo de Reação/efeitos dos fármacos , Tempo de Reação/fisiologia , Tirosina/análogos & derivados , Tirosina/metabolismo
4.
Neuroreport ; 20(17): 1534-7, 2009 Nov 25.
Artigo em Inglês | MEDLINE | ID: mdl-19829160

RESUMO

Age-related depletion of androgens in men results in functional impairments in androgen-responsive tissues, such as the brain, resulting in increased risk for Alzheimer's disease. To investigate the relationship between normal age-related hormone loss and Alzheimer's disease risk, we evaluated the brain and serum levels of androgens and estrogen in aging male rats. We observed that increasing age was associated with a significant reduction in brain levels of the potent androgen dihydrotestosterone and a trend toward decreased testosterone. Brain levels of soluble beta-amyloid were observed to increase with age. Collectively, these findings highlight differences in brain and circulating levels of androgens during aging, and identify an inverse correlation with beta-amyloid levels that may be relevant to Alzheimer's disease risk.


Assuntos
Envelhecimento/metabolismo , Doença de Alzheimer/sangue , Peptídeos beta-Amiloides/metabolismo , Androgênios/sangue , Encéfalo/metabolismo , Doença de Alzheimer/fisiopatologia , Androgênios/análise , Animais , Encéfalo/fisiopatologia , Di-Hidrotestosterona/sangue , Regulação para Baixo/fisiologia , Masculino , Placa Amiloide/metabolismo , Ratos , Fatores de Risco , Testosterona/sangue , Regulação para Cima/fisiologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa